Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue
Vascul Pharmacol. 2023 Aug 10:107208. doi: 10.1016/j.vph.2023.107208. Online ahead of print.ABSTRACTHere we aimed to establish an in vitro engineered heart tissue (EHT) co-morbidity mimicking model of ischemia-reperfusion injury and diabetes. EHTs were generated from primary neonatal rat cardiomyocytes. Hyperglycemic conditions or hyperosmolar controls were applied for one day to model acute hyperglycemia and for seven days to model chronic hyperglycemia. 120 min' simulated ischemia (SI) was followed by 120 min' reperfusion (R) and 1-day follow-up reperfusion (FR). Normoxic controls (N) were not subjected to SI/R. Half of ...
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: J P álóczi Á Paál J Pigler B Kiss A Rhoden Z V Varga P Ferdinandy T Eschenhagen A G örbe Source Type: research
Retraction notice to "Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis" [Vascular Pharmacology 113 (2019) 86-91]
Vascul Pharmacol. 2023 Jan 12:107142. doi: 10.1016/j.vph.2023.107142. Online ahead of print.NO ABSTRACTPMID:37573190 | DOI:10.1016/j.vph.2023.107142 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: Amr Shaaban Hanafy Sherief Abd-Elsalam Mohammed M Dawoud Source Type: research
Organ-specific model of simulated ischemia/reperfusion and hyperglycemia based on engineered heart tissue
Vascul Pharmacol. 2023 Aug 10:107208. doi: 10.1016/j.vph.2023.107208. Online ahead of print.ABSTRACTHere we aimed to establish an in vitro engineered heart tissue (EHT) co-morbidity mimicking model of ischemia-reperfusion injury and diabetes. EHTs were generated from primary neonatal rat cardiomyocytes. Hyperglycemic conditions or hyperosmolar controls were applied for one day to model acute hyperglycemia and for seven days to model chronic hyperglycemia. 120 min' simulated ischemia (SI) was followed by 120 min' reperfusion (R) and 1-day follow-up reperfusion (FR). Normoxic controls (N) were not subjected to SI/R. Half of ...
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: J P álóczi Á Paál J Pigler B Kiss A Rhoden Z V Varga P Ferdinandy T Eschenhagen A G örbe Source Type: research
Retraction notice to "Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis" [Vascular Pharmacology 113 (2019) 86-91]
Vascul Pharmacol. 2023 Jan 12:107142. doi: 10.1016/j.vph.2023.107142. Online ahead of print.NO ABSTRACTPMID:37573190 | DOI:10.1016/j.vph.2023.107142 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - August 12, 2023 Category: Drugs & Pharmacology Authors: Amr Shaaban Hanafy Sherief Abd-Elsalam Mohammed M Dawoud Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelium-dependent vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
GYY4137, a hydrogen sulfide donor, protects against endothelial dysfunction in porcine coronary arteries exposed to myeloperoxidase and hypochlorous acid
CONCLUSIONS: MPO plus H2O2, and HOCl, impair coronary artery endothelial vasorelaxation via inhibition of NO. GYY4137 protects against endothelial dysfunction in arteries exposed to MPO plus H2O2, and HOCl. H2S donors such as GYY4137 are possible therapeutic options to control excessive MPO activity in cardiovascular diseases.PMID:37500030 | DOI:10.1016/j.vph.2023.107199 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Andrew Harper Maike Chapel Grace Hodgson Krzysztof Malinowski Imogen Yates Michael Garle Vera Ralevic Source Type: research
The recent applications of nanotechnology in the diagnosis and treatment of common cardiovascular diseases
Vascul Pharmacol. 2023 Jul 25;152:107200. doi: 10.1016/j.vph.2023.107200. Online ahead of print.ABSTRACTAlmost a third of all fatalities may be attributed to cardiovascular disease (CVD), making it a primary cause of mortalities worldwide. Better diagnostic tools and secure, non-invasive imaging techniques are needed to offer accurate information on CVD progression. Several elements contribute to the success of CVD personalized therapy, and two of the most crucial are accurate diagnosis and early detection. The therapy options available for conditions with a pathogenesis that unfold over decades, such as CVD, are very cond...
Source: Vascular Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Feize Li Haibin Shao Guoer Zhou Bingzhu Wang Yan Xu Wenqing Liang Lin Chen Source Type: research
